Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 4/20 | 0.60 |
| ▸ | CFB | P00751 | 3/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29997756 | 1.00 | DRD2 (0.60) | DRD2SIGMAR1DRD3CFBTMEM97 | |
| SCHEMBL3643723 | 1.00 | DRD2 (0.60) | DRD2SIGMAR1DRD3CFBTMEM97 | |
| SCHEMBL7298696 | 0.79 | DRD2 (0.57) | DRD2SIGMAR1DRD3HTR1A | |
| SCHEMBL4318786 | 0.78 | CHRNB2 (0.54) | DRD2SIGMAR1DRD3CFBTMEM97 | |
| Hydrochloric Acid SCHEMBL10352120 | 0.76 | DRD2 (0.57) | DRD2DRD3LMNA | |
| SCHEMBL7816034 | 0.76 | DRD2 (0.59) | DRD2DRD3 | |
| Pridopidine SCHEMBL166748 | 0.75 | DRD2 (1.00) | DRD2SIGMAR1DRD3 | |
| Pridopidine SCHEMBL29664816 | 0.75 | DRD2 (1.00) | DRD2SIGMAR1DRD3 | |
| SCHEMBL873549 | 0.75 | DRD3 (1.00) | DRD2SIGMAR1DRD3 | |
| SCHEMBL873812 | 0.75 | DRD3 (1.00) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404326-A4 | METHOD OF TREATING PARKINSON'S DISEASE | UPJOHN CO (US) | 2004-06-30 | — | — | EP | claimed |
| EP-1404326-A2 | METHOD OF TREATING PARKINSON'S DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | claimed |
| US-6670378-B2 | Phenylazacycloalkane for treating dyskinesias, dopamine agonists and transplantation of dopamine neurons into the patient's brain | PHARMACIA & UPJOHN COMPANY | 2003-12-30 | — | — | US | claimed |
| US-6653325-B2 | Dyskinesias, by administering a substituted phenylazacycloalkane and a dopamine agonist to the patient | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | claimed |
| US-20020169187-A1 | Method of treating Parkinson's disease | PHARMACIA & UPJOHN COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002056745-A2 | METHOD OF TREATING PARKINSON'S DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-25 | — | — | WO | claimed |
| US-20020049232-A1 | Method of treating parkinson's disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | claimed |
| US-20260060967-A1 | USE OF PRIDOPIDINE FOR TREATING HUNTINGTON DISEASE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-03-05 | — | — | US | disclosed |
| US-12564582-B2 | Use of pridopidine for treating dystonias | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2026-03-03 | — | — | US | disclosed |
| US-20250319076-A1 | USE OF PRIDOPIDINE AND ANALOGS FOR TREATING SYMPTOMS OF HUNTINGTON DISEASE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-10-16 | — | — | US | disclosed |
| US-12390456-B2 | Pridopidine for treating Huntington's disease | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-08-19 | — | — | US | disclosed |
| US-20250082619-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4516356-A2 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-05 | — | — | EP | disclosed |
| EP-3010506-A1 | USE OF HIGH DOSE PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE | Teva Pharmaceuticals International GmbH (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20140378508-A1 | USE OF HIGH DOSE PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE | IVAX International GmbH (CH) | 2014-12-25 | — | — | US | disclosed |
| WO-2014205229-A1 | USE OF HIGH DOSE PRIDOPIDINE FOR TREATING HUNTINGTON'S DISEASE | IVAX International GmbH (CH) | 2014-12-24 | — | — | WO | disclosed |
| EP-2170327-B1 | USE OF DOPAMINE STABILIZERS | CARLSSON A RESEARCH AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20100197712-A1 | USE OF DOPAMINE STABILIZERS | A. CARLSSON RESEARCH AB (SE) | 2010-08-05 | — | — | US | disclosed |
| EP-2170327-A2 | USE OF DOPAMINE STABILIZERS | A.Carlsson Research AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008155357-A2 | USE OF DOPAMINE STABILIZERS | A. CARLSSON RESEARCH AB (SE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169187-A1 | Method of treating Parkinson's disease | PARK7, SNCA, COMT | DRD2 205/4885SIGMAR1 1386/4885DRD3 344/4885 |
| US-20260060967-A1 | USE OF PRIDOPIDINE FOR TREATING HUNTINGTON DISEASE | HTT, DRD2, HTR2C | DRD2 2/4885SIGMAR1 342/4885DRD3 24/4885 |
| US-20250319076-A1 | USE OF PRIDOPIDINE AND ANALOGS FOR TREATING SYMPTOMS OF HUNTINGTON DISEASE | HTT, PARK7, HYPK | DRD2 6/4885SIGMAR1 678/4885DRD3 32/4885 |
| US-20100197712-A1 | USE OF DOPAMINE STABILIZERS | COMT, SNCA, DBH | DRD2 5/4885SIGMAR1 200/4885DRD3 20/4885 |
| US-20020049232-A1 | Method of treating parkinson's disease | PARK7, SNCA, COMT | DRD2 265/4885SIGMAR1 1109/4885DRD3 391/4885 |
| US-12564582-B2 | Use of pridopidine for treating dystonias | KCND2, HTT, BTD | DRD2 17/4885SIGMAR1 395/4885DRD3 233/4885 |
| US-12390456-B2 | Pridopidine for treating Huntington's disease | HTT, HYPK, SNCA | DRD2 16/4885SIGMAR1 800/4885DRD3 87/4885 |
| US-20250082619-A1 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | HTT, PARK7, DRD1 | DRD2 5/4885SIGMAR1 514/4885DRD3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.